Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Muscle and Back Pain Platinum Relief

Canada Type II Ongoing · initiated 2024-08-29

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

PREQUEL SKIN

US Class II Ongoing · initiated 2024-08-28

Microbial contamination of non-sterile Products -

Ashwagandha Supreme

Canada Type I Ongoing · initiated 2024-08-27

Product safety. Do not use this product if you have a dairy allergy.Consult a health care professional if you have used this product and have health concerns.If…

VALACYCLOVIR

Canada Type III Ongoing · initiated 2024-08-27

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Rubicon Research Private Limited

US Class III Ongoing · initiated 2024-08-24

Discoloration

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2024-08-22

Lack of Assurance of Sterility

Option+ Nicotine Gum 2mg Ultra Fresh Fruit

Canada Type III Ongoing · initiated 2024-08-22

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Lupin Pharmaceuticals Inc.

US Class II Terminated · initiated 2024-08-21

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Elevate Oral Care

US Class III Terminated · initiated 2024-08-20

LABELING: LABEL MIX-UP.

JAMP Pyridostigmine Bromide 60mg

Canada Type II Ongoing · initiated 2024-08-20

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

JAMP-ASA EC

Canada Type II Ongoing · initiated 2024-08-20

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Jamp-Rabeprazole

Canada Type II Ongoing · initiated 2024-08-20

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

JAMP-Mycophenolate 250mg

Canada Type I Ongoing · initiated 2024-08-19

Product safety. If you are taking this medication, speak with your pharmacist as soon as possible. Your pharmacist will check if your product is affected by the…

Fagron Compounding Services

US Class II Ongoing · initiated 2024-08-15

Lack of Assurance of Sterility

Biocompatibles UK, Ltd.

US Class III Terminated · initiated 2024-08-15

Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free No…

ACH-SITAGLIPTIN

Canada Type I Ongoing · initiated 2024-08-13

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

FDC Limited

US Class II Ongoing · initiated 2024-08-12

Defective Container: patients are unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Direct Rx

US Class II Ongoing · initiated 2024-08-09

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

TEVA-BUPROPION XL 300MG TABLETS

Canada Type II Ongoing · initiated 2024-08-09

Product quality. Verify if your product is affected.Contact the recalling firm if you have any questions about the recall.Report any health product related side…